NOX 0.00% 9.9¢ noxopharm limited

Ann: Appendix 4D and Half Year Accounts, page-14

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,947 Posts.
    lightbulb Created with Sketch. 790
    Name one post where I have ever ridiculed Cantrixil yet alone persistently. If you can not please remove that post

    JG and the other dir are way too professional to ever call a " spade a sapde" type explanation and are no doubt restricted by confidentiality clauses. I expect on HC, however, poster willing to press the envelope with research and analysis that might join the dots. So I will ask again what year were those mice tested with the NOX66 formulation as described in the description section found at patentscop
    Example 1 Plasma pharmacokinetic studies of idronoxil in rats

    "1 . OBJECTIVE

    The objective of this study in rodents is to determine the plasma pharmacokinetics of idronoxil after rectal delivery and intestinal delivery in lipids (cocoa butter or emulsion).

    2. STUDY DESIGN

    Plasma pharmacokinetic studies rats

    Part (1 ); n=3 rats: Rectal administration of idronoxil in cocoa butter liquid formulation, collection of plasma.

    Part (2); n=3 rats: Intestinal administration (intraduodenal infusion) of idronoxil in lipid formulation, collection of plasma." https://patentscope.wipo.int/search...prevFilter=&sortOption=Pub Date Desc&maxRec=6


    How about engaing the question istead of juct whining that some has the audicidty to ask a question. In fact I am most likely barking up the wonrg tree to which anyone would simple type a year, with a link proving it. It could be something else that was disputed such as this line......

    "There remains a need to obtain therapeutically effective steady state concentrations of idronoxil and related isoflavonoids, especially in clinical interventions involving chemotherapy or radiotherapy, and wherein the purpose of the steady state"
    https://patentscope.wipo.int/search...prevFilter=&sortOption=Pub Date Desc&maxRec=6

    If it is that wording of related isoflavonoids that was being challenged and now handed over I would have thought NOX poster would be thrilled at the prospect of a widened horizon of potential.

    If I am hard on NOX it more likely I have a vendetta against posters who look more like The Stepford wives than serious debaters.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
9.9¢
Change
0.000(0.00%)
Mkt cap ! $29.22M
Open High Low Value Volume
10.0¢ 10.5¢ 9.9¢ $4.773K 48.10K

Buyers (Bids)

No. Vol. Price($)
1 20574 9.9¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 38542 2
View Market Depth
Last trade - 16.10pm 29/11/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.